Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level

References

• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. Bmj. 2014;349:g4797. doi: 10.1136/bmj.g4797.
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373:1119–1132.
   PubMed Web of Science ®Google Scholar
• Liu S, Qi L, Han W, et al. Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma. PLoS One 2014;9:e110218. doi: 10.1371/journal.pone.0110218.
   PubMed Web of Science ®Google Scholar
• Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011;30:225–238.
   PubMed Web of Science ®Google Scholar
• Bimonte S, Barbieri A, Rea D, et al. Morphine promotes tumor angiogenesis and increases breast cancer progression. Biomed Res Int. 2015;2015:161508. doi: 10.1155/2015/161508.
   PubMed Web of Science ®Google Scholar
• Cao LH, Li HT, Lin WQ, et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6:18706. doi: 10.1038/srep18706.
   PubMed Web of Science ®Google Scholar
• Ge ZH, Wang ZX, Yu TL, et al. Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil. Biomed Pharmacother. 2014;68:299–305.
   PubMed Web of Science ®Google Scholar
• Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62:4491–4498.
   PubMed Web of Science ®Google Scholar
• Koodie L, Yuan H, Pumper JA, et al. Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol. 2014;184:1073–1084.
   PubMed Web of Science ®Google Scholar
• Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014;113S1:i4–13.
   Web of Science ®Google Scholar
• Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61:157–182.
   PubMed Web of Science ®Google Scholar
• Niu DG, Peng F, Zhang W, et al. Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget 2015;6:3963–3976.
   PubMed Web of Science ®Google Scholar
• Harimaya Y, Koizumi K, Andoh T, et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187:121–127.
   PubMed Web of Science ®Google Scholar
• Sasamura T, Nakamura S, Iida Y, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 2002;441:185–191.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Grosch S, Schmidtko A, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: Involvement of p53 phosphorylation. Cancer Res. 2003;63:1846–1852.
   PubMed Web of Science ®Google Scholar
• Kim MS, Cheong YP, So HS, et al. Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: Potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase). Biochem Pharmacol. 2001;61:779–786.
   PubMed Web of Science ®Google Scholar
• Liu S, Qi L, Yu Q, et al. Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma. Tumour Biol. 2014;35:8281–8288.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Donovan N, Brennan DJ, et al. Survivin: A promising tumor biomarker. Cancer Lett. 2007;249:49–60.
   PubMed Web of Science ®Google Scholar
• Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5005.
   PubMed Web of Science ®Google Scholar
• Vincent L, Vang D, Nguyen J, et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122:1853–1862.
   PubMed Web of Science ®Google Scholar
• Farooqui M, Geng ZH, Stephenson EJ, et al. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther. 2006;5:611–620.
   PubMed Web of Science ®Google Scholar
• Kampa M, Bakogeorgou E, Hatzoglou A, et al. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol. 1997;335:255–265.
   PubMed Web of Science ®Google Scholar
• Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA. 1990;87:3294–3298.
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen J, Li L, et al. Exogenous morphine inhibits human gastric cancer MGC- 803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev. 2012;13:1377–1382.
   PubMedGoogle Scholar
• Zong J, Pollack GM. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm Res. 2000;17:749–753.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921.
   PubMed Web of Science ®Google Scholar
• Garg H, Suri P, Gupta JC, et al. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016;16:49.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen XG, Hu X, et al. MiR-34a and miR-203 inhibit survivin expression to control cell proliferation and survival in human osteosarcoma cells. J Cancer. 2016;7:1057–1065.
   PubMed Web of Science ®Google Scholar
• Zamparese R, Pannone G, Santoro A, et al. Survivin expression in renal cell carcinoma. Cancer Invest. 2008;26:929–935.
   PubMed Web of Science ®Google Scholar
• Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg. 2011;113:1353–1364.
   PubMed Web of Science ®Google Scholar